
A new study conducted in two high-volume centers examined the risk factors for adverse events in male patients receiving intravesical botulinum toxin A (BTX-A) therapy for bladder dysfunction. The study included 69 men with a median age of 66 years. The results showed that baseline postvoid residual (PVR) of 50 mL or more and BTX-A dose exceeding 100 units were predictors of intermittent self-catheterization (ISC) after BTX-A treatment. However, stress urinary incontinence and a history of radical prostatectomy or bladder outflow obstruction surgery were protective against ISC. Enlarged prostate was associated with an increased risk of urinary tract infections (UTIs). These findings provide valuable insights for counseling male patients about the potential risks of ISC and UTI following BTX-A treatment.
Like
Save
Share